ijms-logo

Journal Browser

Journal Browser

Research Progress of Metabolomics in Health and Disease

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 3785

Special Issue Editor


E-Mail Website
Guest Editor
Department of Basic and Applied Sciences, University of Basilicata, Viale dell’Ateneo Lucano, 10-85100 Potenza, Italy
Interests: liquid chromatography; mass spectrometry; high-resolution mass spectrometry; food; metabolomics; environment
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

To date, metabolomics has emerged as an indispensable platform for the overall analysis of the metabolites, i.e. all the small molecules occurring in the biological systems, including humans, plants, foods, animals and microbes, to discover networks and interactions between them. Moreover, metabolomic studies can help in the discovering of new biomarkers for the diagnosis of health diseases. Studies concerning metabolomics are in continuous progress, allowing new developments in the analytical methods and data analysis tools. This Special Issue is focused on the progresses of the metabolomic technology, both analytical methods and data analysis, in the fields of health and diseases. The topics covered include but are not limited to the application of the modern analytical techniques, such as GC-MS, LC-MS/MS and HRMS, for the comprehensive evaluation of the metabolic fingerprint of biological systems related to the diagnosis and mechanisms elucidations of health diseases involving human or animal samples, or the target identification of specific classes of compounds as well as the manipulation of the big data produced during metabolomic analysis.

Dr. Maria Assunta Acquavia
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • metabolomics
  • health
  • diseases
  • target metabolites
  • mass spectrometry
  • hyphenated techniques

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (5 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 2719 KiB  
Article
Methoxylated Chrysin and Quercetin as Potent Stimulators of Melanogenesis
by Pattara Poungcho, Rita Hairani, Chatchai Chaotham, Wanchai De-Eknamkul and Warinthorn Chavasiri
Int. J. Mol. Sci. 2025, 26(7), 3281; https://doi.org/10.3390/ijms26073281 - 1 Apr 2025
Viewed by 265
Abstract
Polymethoxyflavonoids (PMFs) from plants are known to exhibit melanogenic activity. Very little is known about their structure-activity relationships, and this was the aim of this study. Several series of alkoxy flavonoids were synthesized via semisynthetic and total synthetic pathways. Their structures were identified [...] Read more.
Polymethoxyflavonoids (PMFs) from plants are known to exhibit melanogenic activity. Very little is known about their structure-activity relationships, and this was the aim of this study. Several series of alkoxy flavonoids were synthesized via semisynthetic and total synthetic pathways. Their structures were identified by NMR analyses, followed by evaluating their potency on the stimulation of melanogenesis using mouse B16F10 and human MNT-1 cells. Among more than twenty methoxylated flavonoids, 5,7-dimethoxychrysin (dimethoxylated chrysin, F1) and 3,3′,4′,5,7-pentamethoxyquercetin (pentamethoxylated quercetin, F21) appeared to be the most active melanogenic-stimulating compounds in a dose-dependent manner. Both compounds showed no effect on cell viability as determined by MTT assay. The structure-activity relationship study of PMFs revealed that the -OCH3 substituent at 5 and 7 positions of A-ring are the most important as melanogenic-stimulating part (e.g., 5,7-dimethoxychrysin, F1) followed by at 3′ and 4′ positions of B-ring, and at 3 positions of C-ring (e.g., 3,3′,4′,5,7-pentamethoxyquercetin, F21), Therefore, both natural methoxylated flavonoid derivatives of chrysin and quercetin have a potential to be developed further as melanogenic stimulators. Full article
(This article belongs to the Special Issue Research Progress of Metabolomics in Health and Disease)
Show Figures

Figure 1

23 pages, 3859 KiB  
Article
Deciphering Colorectal Cancer–Hepatocyte Interactions: A Multiomics Platform for Interrogation of Metabolic Crosstalk in the Liver–Tumor Microenvironment
by Alisa B. Nelson, Lyndsay E. Reese, Elizabeth Rono, Eric D. Queathem, Yinjie Qiu, Braedan M. McCluskey, Alexandra Crampton, Eric Conniff, Katherine Cummins, Ella Boytim, Senali Dansou, Justin Hwang, Sandra E. Safo, Patrycja Puchalska, David K. Wood, Kathryn L. Schwertfeger and Peter A. Crawford
Int. J. Mol. Sci. 2025, 26(5), 1976; https://doi.org/10.3390/ijms26051976 - 25 Feb 2025
Viewed by 648
Abstract
Metabolic reprogramming is a hallmark of cancer, enabling tumor cells to adapt to and exploit their microenvironment for sustained growth. The liver is a common site of metastasis, but the interactions between tumor cells and hepatocytes remain poorly understood. In the context of [...] Read more.
Metabolic reprogramming is a hallmark of cancer, enabling tumor cells to adapt to and exploit their microenvironment for sustained growth. The liver is a common site of metastasis, but the interactions between tumor cells and hepatocytes remain poorly understood. In the context of liver metastasis, these interactions play a crucial role in promoting tumor survival and progression. This study leverages multiomics coverage of the microenvironment via liquid chromatography and high-resolution, high-mass-accuracy mass spectrometry-based untargeted metabolomics, 13C-stable isotope tracing, and RNA sequencing to uncover the metabolic impact of co-localized primary hepatocytes and a colon adenocarcinoma cell line, SW480, using a 2D co-culture model. Metabolic profiling revealed disrupted Warburg metabolism with an 80% decrease in glucose consumption and 94% decrease in lactate production by hepatocyte–SW480 co-cultures relative to SW480 control cultures. Decreased glucose consumption was coupled with alterations in glutamine and ketone body metabolism, suggesting a possible fuel switch upon co-culturing. Further, integrated multiomics analysis indicates that disruptions in metabolic pathways, including nucleoside biosynthesis, amino acids, and TCA cycle, correlate with altered SW480 transcriptional profiles and highlight the importance of redox homeostasis in tumor adaptation. Finally, these findings were replicated in three-dimensional microtissue organoids. Taken together, these studies support a bioinformatic approach to study metabolic crosstalk and discovery of potential therapeutic targets in preclinical models of the tumor microenvironment. Full article
(This article belongs to the Special Issue Research Progress of Metabolomics in Health and Disease)
Show Figures

Figure 1

19 pages, 3204 KiB  
Article
Microbiota Co-Metabolism Alterations Precede Changes in the Host Metabolism in the Early Stages of Diet-Induced MASLD in Wistar Rats
by María Martín-Grau, Pilar Casanova, Laura Moreno-Morcillo, José Manuel Morales, Vannina G. Marrachelli and Daniel Monleón
Int. J. Mol. Sci. 2025, 26(3), 1288; https://doi.org/10.3390/ijms26031288 - 2 Feb 2025
Viewed by 1088
Abstract
Metabolic-dysfunction-associated steatotic liver disease (MASLD) affects around 30% of the global population. The sexual dimorphism and gut microbiota play an important role in the early development of MASLD. The main objective of this research was to investigate metabolic changes during the early subclinical [...] Read more.
Metabolic-dysfunction-associated steatotic liver disease (MASLD) affects around 30% of the global population. The sexual dimorphism and gut microbiota play an important role in the early development of MASLD. The main objective of this research was to investigate metabolic changes during the early subclinical MASLD progression, for identifying the sequence of events and evaluating the impact of sexual dimorphism and the microbiota on the initial stages of MASLD development. Male and female Wistar rats 18 weeks old were randomly divided into different groups and fed a chow diet or a 45% high-fat diet for 21 weeks. Every three weeks, samples of serum, urine, and faeces were collected and studied by metabolomics. Furthermore, the liver was analysed at the endpoint. In addition, the gut microbiota was analysed from faecal samples over time using 16S rRNA gene-targeted group-specific primers. Our results revealed that three weeks on an HFD reduced the bacterial diversity in the faecal microbiota of Wistar rats, accompanied by changes in the faecal and urine metabolome. The HFD-induced alterations in microbiota-related co-metabolites in the liver, blood, urine, and faeces indicate a significant role of host–microbiota co-metabolism changes in the early stages of MASLD. In this study, we provide a comprehensive longitudinal analysis, detailing the sequence of events in the early development of MASLD. Our findings suggest that alterations in the gut microbiota diversity and co-metabolism occur before changes in host metabolism in the early onset of liver steatosis, a subclinical phase of MASLD. Full article
(This article belongs to the Special Issue Research Progress of Metabolomics in Health and Disease)
Show Figures

Figure 1

Review

Jump to: Research

28 pages, 1205 KiB  
Review
Application of Multiomics in Perinatology: A Metabolomics Integration-Focused Review
by Alice Bosco, Francesca Arru, Alessandra Abis, Vassilios Fanos and Angelica Dessì
Int. J. Mol. Sci. 2025, 26(9), 4164; https://doi.org/10.3390/ijms26094164 - 27 Apr 2025
Viewed by 161
Abstract
Precision medicine stems from a new approach to the prevention, diagnosis and treatment of patients, due to the shift in focus away from pathology and towards the uniqueness of the individual, personalising the diagnostic–therapeutic pathway. This paradigm shift has been made possible by [...] Read more.
Precision medicine stems from a new approach to the prevention, diagnosis and treatment of patients, due to the shift in focus away from pathology and towards the uniqueness of the individual, personalising the diagnostic–therapeutic pathway. This paradigm shift has been made possible by the emergence of new high-throughput technologies capable of generating large amounts of data on multiple levels of a biological system, identifying pathology-related genes, transcripts, proteins and metabolites. Metabolomics plays a primary role in this context, providing, through non-invasive sampling, a very close image of the phenotype of the organism being studied by detecting metabolites, end products downstream of gene transcription, present in cells, tissues, organs and biological fluids. The enormous amount of data that these modern technologies make available, together with the need to elucidate the complex interplay of the various biological levels by combining data from distinct omics, has led to the need to employ advanced informatics techniques, among which artificial intelligence has recently emerged. These innovations are of great interest in the field of perinatology, representing an attempt to optimise the diagnostic timeline for the most critical newborns. In addition, they may contribute to the improvement of prevention strategies available to date. All these contributions prove to be crucial at very vulnerable life stages, allowing crucial intervention opportunities. In this review, we have analysed studies that have integrated metabolomics with at least one other omics in the perinatal field, attempting to highlight the usefulness of multiomics integration and the different methods employed. Full article
(This article belongs to the Special Issue Research Progress of Metabolomics in Health and Disease)
Show Figures

Figure 1

20 pages, 1951 KiB  
Review
Advances in Metabolomics: A Comprehensive Review of Type 2 Diabetes and Cardiovascular Disease Interactions
by Lilian Fernandes Silva and Markku Laakso
Int. J. Mol. Sci. 2025, 26(8), 3572; https://doi.org/10.3390/ijms26083572 - 10 Apr 2025
Viewed by 454
Abstract
Type 2 diabetes (T2D) and cardiovascular diseases (CVDs) are major public health challenges worldwide. Metabolomics, the exhaustive assessment of metabolites in biological systems, offers important insights regarding the metabolic disturbances related to these disorders. Recent advances toward the integration of metabolomics into clinical [...] Read more.
Type 2 diabetes (T2D) and cardiovascular diseases (CVDs) are major public health challenges worldwide. Metabolomics, the exhaustive assessment of metabolites in biological systems, offers important insights regarding the metabolic disturbances related to these disorders. Recent advances toward the integration of metabolomics into clinical practice to facilitate the discovery of novel biomarkers that can improve the diagnosis, prognosis, and treatment of T2D and CVDs are discussed in this review. Metabolomics offers the potential to characterize the key metabolic alterations associated with disease pathophysiology and treatment. T2D is a heterogeneous disease that develops through diverse pathophysiological processes and molecular mechanisms; therefore, the disease-causing pathways of T2D are not completely understood. Recent studies have identified several robust clusters of T2D variants representing biologically meaningful, distinct pathways, such as the beta cell and proinsulin cluster related to pancreatic insulin secretion, obesity, lipodystrophy, the liver/lipid cluster, glycemia, and blood pressure, and metabolic syndrome clusters representing different pathways causing insulin resistance. Regarding CVDs, recent studies have allowed the metabolomic profile to delineate pathways that contribute to atherosclerosis and heart failure, as well as to the development of targeted therapy. This review also covers the role of metabolomics in integrated metabolic genomics and other omics platforms to better understand disease mechanisms, along with the transition toward precision medicine. This review further investigates the use of metabolomics in multi-metabolite modeling to enhance risk prediction models for predicting the first occurrence of major adverse cardiovascular events among individuals with T2D, highlighting the value of such approaches in optimizing the preventive and therapeutic models used in clinical practice. Full article
(This article belongs to the Special Issue Research Progress of Metabolomics in Health and Disease)
Show Figures

Figure 1

Back to TopTop